Kimberly-Clark 3Q 2026: Revenue $4.13B, EPS $5.37 — 10-Q Summary

Kimberly-Clark reported Q3 2026 revenue of $4.13B, down 0.4% YoY, with net income rising 302% to $1.79B due to a $1.4B gain. Organic sales fell 1.3%, while North America sales grew 0.9%. Gross margin declined to 34.9%. The Kenvue acquisition was completed on November 2, 2026.

Original reporting
Published Nov 5, 2026, 5:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 5:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Kimberly-Clark 3Q 2026: Revenue $4.13B, EPS $5.37 — 10-Q Summary — source image
Decision brief

The 30-second read

$KMBNeutralMed
01

Why it matters

The earnings release provides new data on sales trends, margins, and one‑time gains, shaping short‑term price expectations.

02

Market read

The filing offers fresh material numbers for a large‑cap defensive stock, influencing sector sentiment and short‑term trading decisions.

03

What to watch

Integration costs from the recent Kenvue acquisition could erode profitability beyond 2029, and China disruption remains a risk.

Relevance 8/10Novelty 8/10Timing: post-market filing

Background

Kimberly‑Clark filed its Q3 2026 10‑Q, reporting flat revenue, a large after‑tax gain, and integration costs from the Kenvue acquisition.

Company-level read

Ticker impact

$KMBNeutralHigh confidence
Context

10-Q filing shows Q3 net sales flat YoY, EPS $5.37 boosted by $1.4B gain on IFP transaction and integration charges from Kenvue deal.

Expected impact

mixed pressure as investors weigh the large gain against weak organic growth

Evidence & confidence

The filing provides fresh, material numbers for a large cap; the gain is sizable but not recurring, while organic sales and margins fell.

Market effects

Consumer staples may see modest pressure as peers' organic growth slows, highlighting demand softness.

North America sales modestly up, but international personal care weakness could weigh on global consumer‑goods sentiment.

Large‑cap earnings updates influence broader market direction, especially for defensive sectors.

Counterpoint

The $1.4B gain may mask deeper demand issues; a short position could benefit if organic decline persists.

Key entities

  • Kimberly‑Clark Corp.

    Consumer‑goods manufacturer reporting Q3 results.

  • Kenvue

    Recent acquisition whose integration costs will affect future earnings.

Related articles

$KMBMedAI 8/10

Kimberly-Clark’s Dividend Is Up 392% Since 1999. Can Its $49 Billion Deal Put That at Risk?

Kimberly-Clark (KMB) has increased its dividend by 392% since 1999, with a current quarterly payout of $1.28. The company's $49 billion acquisition of Kenvue, funded partly by debt, may test its dividend streak. In 2025, free cash flow was $1.64 billion, slightly below the $1.66 billion paid in dividends. Management aims for reduced leverage and cost synergies to support earnings and the dividend.

$KMBMedAI 8/10

Kimberly-Clark backs 2026 outlook despite China disruptions

Kimberly-Clark reported Q3 2026 net sales of $4.13B, down 0.4% YoY, with adjusted EPS up 17.2% to $1.70. China disruptions and North American inventory movements impacted sales. The company reaffirmed its 2026 outlook, expecting mid-single-digit adjusted operating profit growth and high single-digit adjusted EPS growth.

$KMBMed

Kimberly-Clark Corp (KMB) (Q3 2026) Earnings Call Highlights: Kenvue Deal Closes

Kimberly-Clark (KMB) CEO Mike Hsu and CFO Nelson Urdaneta discussed Q3 2026 earnings, Kenvue integration, and 2027 outlook. Hsu highlighted Kenvue's 3% organic growth and progress in brand performance. Urdaneta cited cost-mitigating actions and easier Q4 comparisons. They addressed North America's share performance, diaper market dynamics, and synergy plans, including $1.9B in cost savings. KMB maintained fiscal 2026 guidance despite challenges.